Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00167180 · FLOW

Participant flow

Post Transplant Donor Lymphocyte Infusion · Source last updated 2019-07-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Patients who have failed or refused Gleevec (TM) therapy and will receive Donor Lymphocyte Infusion. Donor Lymphocyte Infusion: donor cells infused over 2 hrs at cell dose of 0.5 dx 10\^8 CD3+T-cells/kg
    id
    FG000
    title
    Chronic Myelogenous Leukemia (CML)
  2. description
    Patients with non-CML or CML who have failed DLI and will receive Induction Chemotherapy + DLI. Induction Chemotherapy + DLI: Fludarabine 25 mg/m2 IV Cyclosphosphamide 60 mg/kg IV Donor Lymphocyte Infusion (DLI)
    id
    FG001
    title
    Non-CML or CML Failing Donor Lymphocyte Infusion
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        57
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        57
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
During the recruitment period of the study, the donor lymphocyte infusion (DLI) was reduced from 1.0 x 10\^8 CD3+ T-cells/kg to 0.5 x 10\^8 CD3+ T-cells/kg due to an excess rate and intensity of graft vs. host disease.
Complete source fields
groups
  1. description
    Patients who have failed or refused Gleevec (TM) therapy and will receive Donor Lymphocyte Infusion. Donor Lymphocyte Infusion: donor cells infused over 2 hrs at cell dose of 0.5 dx 10\^8 CD3+T-cells/kg
    id
    FG000
    title
    Chronic Myelogenous Leukemia (CML)
  2. description
    Patients with non-CML or CML who have failed DLI and will receive Induction Chemotherapy + DLI. Induction Chemotherapy + DLI: Fludarabine 25 mg/m2 IV Cyclosphosphamide 60 mg/kg IV Donor Lymphocyte Infusion (DLI)
    id
    FG001
    title
    Non-CML or CML Failing Donor Lymphocyte Infusion
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        57
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        57
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
During the recruitment period of the study, the donor lymphocyte infusion (DLI) was reduced from 1.0 x 10\^8 CD3+ T-cells/kg to 0.5 x 10\^8 CD3+ T-cells/kg due to an excess rate and intensity of graft vs. host disease.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice